Accordingly, inhibition of glutathione biosynthesis has been harnessed as a therapeutic strategy in various preclinical models, including KRAS-driven pancreatic cancer and non-small cell lung cancer19,20,38. The gene discussed is KRAS; the disease is familial pancreatic carcinoma.